Genfit Valuation
Is GNFT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GNFT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GNFT (€4.16) is trading above our estimate of fair value (€1.46)
Significantly Below Fair Value: GNFT is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GNFT?
Key metric: As GNFT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is GNFT's PE Ratio? | |
|---|---|
| PE Ratio | 9.3x |
| Earnings | €22.27m |
| Market Cap | €207.01m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.6x |
| Enterprise Value/EBITDA | 9.8x |
| PEG Ratio | 0.2x |
Price to Earnings Ratio vs Peers
How does GNFT's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.6x | ||
ALERS Eurobio Scientific Société anonyme | 38.9x | 29.0% | €258.1m |
OSE OSE Immunotherapeutics | 4.2x | -72.5% | €191.2m |
ALGEN genOway Société anonyme | 26.8x | n/a | €33.6m |
PCA PCAS | 12.5x | n/a | €109.9m |
GNFT Genfit | 9.3x | 41.2% | €207.0m |
Price-To-Earnings vs Peers: GNFT is good value based on its Price-To-Earnings Ratio (9.3x) compared to the peer average (20.6x).
Price to Earnings Ratio vs Industry
How does GNFT's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: GNFT is good value based on its Price-To-Earnings Ratio (9.3x) compared to the European Biotechs industry average (26.8x).
Price to Earnings Ratio vs Fair Ratio
What is GNFT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 9.3x |
| Fair PE Ratio | 23.8x |
Price-To-Earnings vs Fair Ratio: GNFT is good value based on its Price-To-Earnings Ratio (9.3x) compared to the estimated Fair Price-To-Earnings Ratio (23.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €4.16 | €9.45 +127.4% | 17.0% | €11.50 | €7.00 | n/a | 4 |
| Nov ’25 | €5.40 | €9.45 +75.0% | 17.0% | €11.50 | €7.00 | n/a | 4 |
| Oct ’25 | €4.67 | €9.45 +102.6% | 17.0% | €11.50 | €7.00 | n/a | 4 |
| Sep ’25 | €3.91 | €9.33 +138.5% | 17.3% | €11.50 | €7.00 | n/a | 4 |
| Aug ’25 | €4.00 | €9.33 +133.1% | 17.3% | €11.50 | €7.00 | n/a | 4 |
| Jul ’25 | €3.73 | €9.48 +154.4% | 17.7% | €11.50 | €7.00 | n/a | 4 |
| Jun ’25 | €4.72 | €9.38 +98.7% | 16.2% | €11.50 | €7.00 | n/a | 5 |
| May ’25 | €3.20 | €9.38 +193.1% | 16.2% | €11.50 | €7.00 | n/a | 5 |
| Apr ’25 | €3.34 | €9.38 +180.8% | 16.2% | €11.50 | €7.00 | n/a | 5 |
| Mar ’25 | €3.25 | €9.38 +189.1% | 16.2% | €11.50 | €7.00 | n/a | 5 |
| Feb ’25 | €3.55 | €9.60 +170.4% | 17.3% | €11.50 | €7.00 | n/a | 4 |
| Jan ’25 | €3.54 | €9.26 +161.6% | 15.5% | €11.50 | €7.00 | n/a | 5 |
| Dec ’24 | €2.99 | €9.26 +210.2% | 15.5% | €11.50 | €7.00 | n/a | 5 |
| Nov ’24 | €3.01 | €9.26 +208.2% | 15.5% | €11.50 | €7.00 | €5.40 | 5 |
| Oct ’24 | €3.14 | €9.26 +194.9% | 15.5% | €11.50 | €7.00 | €4.67 | 5 |
| Sep ’24 | €3.31 | €9.66 +192.3% | 10.5% | €11.50 | €8.80 | €3.91 | 5 |
| Aug ’24 | €3.37 | €9.66 +186.6% | 10.5% | €11.50 | €8.80 | €4.00 | 5 |
| Jul ’24 | €3.50 | €9.64 +175.4% | 14.3% | €11.50 | €7.90 | €3.73 | 5 |
| Jun ’24 | €3.76 | €8.55 +127.4% | 18.7% | €11.00 | €6.60 | €4.72 | 4 |
| May ’24 | €3.70 | €9.20 +148.6% | 14.3% | €11.00 | €7.90 | €3.20 | 3 |
| Apr ’24 | €3.70 | €10.15 +174.3% | 19.7% | €13.00 | €7.90 | €3.34 | 4 |
| Mar ’24 | €4.02 | €10.15 +152.4% | 19.7% | €13.00 | €7.90 | €3.25 | 4 |
| Feb ’24 | €3.87 | €10.15 +162.3% | 19.7% | €13.00 | €7.90 | €3.55 | 4 |
| Jan ’24 | €3.97 | €10.15 +155.8% | 19.7% | €13.00 | €7.90 | €3.54 | 4 |
| Dec ’23 | €3.42 | €10.15 +196.4% | 19.7% | €13.00 | €7.90 | €2.99 | 4 |
| Nov ’23 | €4.01 | €9.90 +146.9% | 19.6% | €13.00 | €7.90 | €3.01 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Sanofi
€114.7b
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.
SAN
€91.47
7D
-4.4%
1Y
7.1%
Eurofins Scientific
€8.6b
Provides various analytical testing and laboratory services worldwide.
ERF
€45.57
7D
-1.3%
1Y
-11.3%
Theranexus Société Anonyme
€3.9m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€0.50
7D
1.2%
1Y
-58.0%